Brian Miller, DO
Allergy · Georgetown, TXNPI 1790882108
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.9% of the total across 553 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 37 manufacturers reported payments, led by AstraZeneca at 28.6% of the total.
Across 553 payments — averaging $26.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$4K
- GSK$3K
- Sanofi$990
- Takeda Pharmaceuticals U.S.A., Inc.$699
- Regeneron Healthcare Solutions, Inc.$683
- Mylan Specialty L.p.$528
- plus $5K from 31 others
Across 16 payments — averaging $9590.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$96K
- Teva Pharmaceuticals USA, Inc.$32K
- Acerta Pharma LLC$17K
- GSK$6K
- Alk-abello, Inc$3K
What the payments were for
- Consulting fees$901%
- Food & beverage$14,39498%
- Education$2151%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 107 | $4,201 |
| GSK | 162 | $2,947 |
| Sanofi | 34 | $990 |
| Takeda Pharmaceuticals U.S.A., Inc. | 27 | $699 |
| Regeneron Healthcare Solutions, Inc. | 25 | $683 |
| Mylan Specialty L.p. | 24 | $528 |
| Blueprint Medicines Corporation | 15 | $463 |
| Grifols USA, LLC | 19 | $438 |
| Pfizer | 10 | $408 |
| Amgen | 16 | $405 |
| Novartis | 19 | $299 |
| Genentech USA, Inc. | 6 | $225 |
| ARS Pharmaceuticals Operations, Inc. | 6 | $214 |
| Boehringer Ingelheim | 9 | $191 |
| Octapharma USA, Inc. | 8 | $190 |
| AbbVie | 4 | $186 |
| Teva Pharmaceuticals USA, Inc. | 3 | $153 |
| Alk-abello, Inc | 3 | $151 |
| Biohaven Pharmaceuticals, Inc. | 7 | $151 |
| Shire North American Group Inc | 6 | $150 |
| CSL Behring | 5 | $143 |
| Johnson & Johnson | 1 | $126 |
| Ionis Pharmaceuticals, Inc. | 4 | $108 |
| Sanofi-aventis U.S. LLC | 2 | $93 |
| Kaleo, Inc. | 4 | $86 |
| Hikma Pharmaceuticals USA | 4 | $69 |
| Organon | 3 | $65 |
| Sunovion Pharmaceuticals Inc. | 6 | $62 |
| Verona Pharma, Inc. | 2 | $54 |
| Optinose US, Inc. | 3 | $50 |
| USWM, LLC | 2 | $38 |
| Eyevance Pharmaceuticals LLC | 2 | $31 |
| Incyte Corporation | 1 | $28 |
| Azurity Pharmaceuticals, Inc. | 1 | $22 |
| Viatris Specialty LLC | 1 | $20 |
| Seqirus USA Inc | 1 | $16 |
| Merck | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,699 in reported general payments places this provider in the 85th percentile of 69 allergy providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 104 | $85,353 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 39 | $25,263 |
| Nurtec OdtRimegepant Sulfate | 11 | $22,291 |
| XhanceFluticasone Propionate | 12 | $10,373 |
| Epinephrine | 41 | $5,722 |
| Ipratropium Bromide | 141 | $3,675 |
| RyaltrisOlopatadine Hcl/Mometasone | 14 | $3,198 |
| Azelastine Hcl | 70 | $2,049 |
| Levocetirizine Dihydrochloride | 72 | $1,536 |
| Mometasone Furoate | 24 | $1,483 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 11 | $1,366 |
| Famotidine | 83 | $1,145 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 45 | $839 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 12 | $785 |
| Desmopressin Acetate | 18 | $540 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $2,947 | $85,353104 claims |
| AstraZenecaBreztri Aerosphere | $4,201 | $25,26339 claims |
| PfizerNurtec Odt | $408 | $22,29111 claims |
| Optinose US, Inc.Xhance | $50 | $10,37312 claims |
| Hikma Pharmaceuticals USAEpinephrine, Ryaltris | $69 | $8,92155 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 69 allergy providers in Texas.
Other allergy in Georgetown
- Sheila AmarGeorgetown$6K
- Gary GrossDallas$602K
- Rene LeonSouthlake$48K
- Christina HuddlestonDallas$26K
- Alireza ShakouriSouthlake$17K
- Zachary MarshallRoanoke$17K
- Stuart AbramsonSan Angelo$16K
- Patricia DingerSan Antonio$15K
- Carlos VitalHouston$14K
- David FuentesBoerne$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.